Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~The following is an abbreviated list of inclusion criteria:~* Adults ≥ 18 years with type 1 or 2 diabetes mellitus~* Decrease in vision determined to be primarily the result of DME in the study eye~* BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye~Exclusion Criteria:~The following is an abbreviated list of exclusion criteria:~* Laser photocoagulation (panretinal or macular) in the study eye within 90 days of day 1~* Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of day 1~* Previous treatment with anti-angiogenic drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc.) within 90 days of day 1~* Active proliferative diabetic retinopathy (PDR) in the study eye~* Uncontrolled diabetes mellitus~* Only 1 functional eye even if that eye is otherwise eligible for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macular Laser Photocoagulation Treatment (Control) (Type: ACTIVE_COMPARATOR): Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
- Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 (Type: EXPERIMENTAL): Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
- Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 (Type: EXPERIMENTAL): Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).